Stockscreener 앱 받기
20.83
1.02%
0.21
시간 외 거래:
20.83
Immunome Inc 주식(IMNM)의 최신 뉴스
Behavioral Patterns of IMNM and Institutional Flows - Stock Traders Daily
HC Wainwright & Co. initiates coverage of Immunome (IMNM) with buy recommendation - MSN
This Sezzle analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN
Stephens & Co. Maintains Immunome (IMNM) Overweight Recommendation - MSN
Immunome Inc Stock (ISIN: US45254C1062) Eyes Upside as Lock-Up Expires Today Amid Short-Term Buy Sig - AD HOC NEWS
Forecast Cut: What is the long term forecast for Immunome Inc stockBond Market & Fast Gain Stock Trading Tips - baoquankhu1.vn
Certain Stock Options of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2026. - marketscreener.com
Certain Common Stock of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 17-MAR-2026. - marketscreener.com
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% - AOL.com
Pivotal bioVenture Partners Investment Advisor LLC Invests $5.88 Million in Immunome, Inc. $IMNM - MarketBeat
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing - AOL.com
Loss Report: Is Immunome Inc forming a breakout pattern2026 Risk Factors & Weekly Stock Breakout Alerts - baoquankhu1.vn
Bienaime buys Immunome (IMNM) shares worth $43,670 - Investing.com Nigeria
Insider Buying: Jean Bienaime Acquires Additional Shares of Immu - GuruFocus
Immunome (NASDAQ:IMNM) Director Acquires $21,550.00 in Stock - MarketBeat
Bienaime buys Immunome (IMNM) shares worth $43,670 By Investing.com - Investing.com UK
Immunome (IMNM) director buys 2,000 shares in open market - Stock Titan
Craig-Hallum Initiates Coverage of Immunome (IMNM) with Buy Recommendation - MSN
A Look At Immunome (IMNM) Valuation After Narrower 2025 Loss And New US$156 Million Shelf Registration - simplywall.st
Immunome: Upcoming NDA, Valuation, And Investment Case (NASDAQ:IMNM) - Seeking Alpha
Immunome (IMNM) to Release Earnings on Wednesday - MarketBeat
(IMNM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Immunome (NASDAQ:IMNM) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Is Immunome Inc forming a breakout patternJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: MetaVia (MTVA), Immunome (IMNM) - The Globe and Mail
Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative? - finance.yahoo.com
Whale Trades: How do insiders feel about Immunome IncMarket Sentiment Review & Entry and Exit Point Strategies - baoquankhu1.vn
HC Wainwright Brokers Raise Earnings Estimates for Immunome - MarketBeat
Immunome (IMNM) TTM Net Loss Of US$212 Million Reinforces Bearish Profitability Narratives - Sahm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
HC Wainwright Analysts Boost Earnings Estimates for Immunome - MarketBeat
IMNM: Stephens & Co. Lowers Price Target to $30, Maintains Overw - GuruFocus
Immunome (IMNM): Craig-Hallum Raises Price Target to $36.00 and - GuruFocus
Immunome (NASDAQ:IMNM) Price Target Raised to $36.00 - MarketBeat
Stephens Cuts Immunome (NASDAQ:IMNM) Price Target to $30.00 - MarketBeat
Decoding Immunome Inc (IMNM): A Strategic SWOT Insight - GuruFocus
Immunome (IMNM) Reports Wider Losses and Revenue Decline - GuruFocus
Immunome 2025 Net Loss Narrows - marketscreener.com
Immunome (IMNM) Projects Strong Cash Position and Promising Drug Developments - GuruFocus
Earnings Flash (IMNM) Immunome Posts Full Year 2025 Loss $2.43, vs. FactSet Est of $2.24 Loss - marketscreener.com
Immunome: Q4 Earnings Insights - Benzinga
IMNM: Net loss improved to $212.4M in 2025, with $653.5M cash supporting late-stage oncology pipeline - TradingView
Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Immunome (IMNM) 2025 10-K: Phase 3 varegacestat data and ADC pipeline - Stock Titan
Immunome (IMNM) posts 2025 loss but scores major Phase 3 cancer win - Stock Titan
Immunome Reports Full Year 2025 Financial Results and Provides Business Update - Business Wire
TD Asset Management Inc Purchases 95,750 Shares of Immunome, Inc. $IMNM - MarketBeat
IMNM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors - simplywall.st
Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development - Insider Monkey
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Immunome, Inc. (IMNM) Investor Outlook: Exploring a Promising 60% Upside in the Biotech Sector - DirectorsTalk Interviews
Private Capital Advisors Inc. Has $1.38 Million Stake in Immunome, Inc. $IMNM - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):